Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx (Nasdaq: LUNG) closed a five-year credit facility with Perceptive Advisors for up to $60 million on March 4, 2026. The facility funds a $40 million term loan drawn at closing to refinance existing debt and a conditional $20 million undrawn option through end of 2027.
The loan is interest-only until its 2031 maturity, bears interest at one-month Term SOFR (3.75% floor) plus 7.0%, and allows 2.0% paid-in-kind interest at the company’s option for three years.
Pulmonx (Nasdaq: LUNG) will report its fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live archived webcast will be available on the company investor website.
Pulmonx (Nasdaq: LUNG) announced that on December 1, 2025 it granted equity awards under its 2025 Inducement Plan totaling 1,625,000 shares to two executives hired in Q4 2025, including CFO Derrick Sung.
The awards comprise 1,225,000 RSUs (Mr. Sung received 1,200,000 RSUs) that vest 25% after one year and then quarterly over three years. Mr. Sung also received up to 400,000 PSUs subject to a time-based vesting schedule (33% at one year, then quarterly over two years) and a 60-trading-day average closing price performance condition. The Inducement Plan was adopted by the board in November 2025 and complies with Nasdaq Rule 5635(c)(4).
Pulmonx (Nasdaq: LUNG) reported third quarter 2025 results for the period ended September 30, 2025: total revenue $21.5M (+5% vs Q3 2024; +4% constant currency), with U.S. revenue $14.0M (+1% YoY) and international revenue $7.5M (+15% YoY; +9% constant currency). Gross profit was $16.1M and gross margin 75%. Operating expenses were $30.4M and net loss was $14.0M ($0.34 per share). Adjusted EBITDA loss was $8.2M. Cash and cash equivalents totaled $76.5M at quarter end. Pulmonx updated full-year 2025 guidance to $89M–$90M revenue, ~73% gross margin, and $125M–$126M operating expenses (including ~$21M stock-based compensation).
Pulmonx (NASDAQ: LUNG) announced a management transition and preliminary third quarter 2025 revenue on October 27, 2025. Glen French is reappointed President and CEO effective immediately; Derrick Sung will become COO and CFO effective November 3, 2025. Two executives, Steve Williamson and Mehul Joshi, resigned and will serve as advisors through December 1, 2025. The company reported preliminary, unaudited Q3 2025 revenue of approximately $21.5 million. Third quarter 2025 financial results and a conference call were rescheduled for November 12, 2025 at 1:30 p.m. PT / 4:30 p.m. ET. The revenue figure is preliminary and subject to revision when full results are released.
Pulmonx (Nasdaq: LUNG) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day. Interested parties must register online to receive dial‑in details and a personal PIN. A live and archived webcast will be available in the Investors section at https://investors.pulmonx.com/.
Pulmonx (NASDAQ:LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4 at 1:30 PM PT in Boston, with a webcast available. Additionally, management will attend the Lake Street Best Ideas Growth Conference on September 11 in New York for one-on-one meetings. Investors can access the Wells Fargo fireside chat webcast through Pulmonx's investor relations website.
Pulmonx (Nasdaq: LUNG) reported its Q2 2025 financial results, achieving total revenue of $23.9 million, representing a 15% year-over-year increase. The company's performance was driven by strong international growth of 32% ($9.1 million), while U.S. revenue grew 6% ($14.7 million).
The company maintained a gross margin of 72% but reported a net loss of $15.2 million ($0.38 per share). Due to slower-than-expected U.S. revenue conversion, Pulmonx revised its full-year 2025 guidance down to $90-92 million from the previous $96-98 million forecast. Operating expenses are now expected to be $128-130 million, reduced from prior guidance of $133-135 million.
Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.
Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Pulmonx's website at investors.pulmonx.com.
Pulmonx (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has scheduled its Q2 2025 financial results announcement for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live and archived webcast through the company's investor relations website.